Island Pharmaceuticals Limited (ASX:ILA)

Market Cap	109.49M +123.2%
Revenue (ttm)	62.85K -84.3%
Net Income	-7.20M
EPS	-0.03
Shares Out	295.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	563,886
Open	0.3850
Previous Close	0.3800
Day's Range	0.3650 - 0.3850
52-Week Range	0.1300 - 0.6300
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ILA

Financial Performance

In fiscal year 2025, Island Pharmaceuticals's revenue was 118,910, a decrease of -90.57% compared to the previous year's 1.26 million. Losses were -3.92 million, 36.9% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error